Close Relationship of Alzheimer’s Disease (AD) and Glucose Dysregulation

Hiroshi BANDO, MD, PhD 1,2*
1Tokushima University/Medical Research, Japan
2Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Japan

*Corresponding author: Hiroshi BANDO, MD, PhD, FACP, Tokushima University/Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan, Tel: +81-90-3187-2485

Several evidence have been reported about dietary types on cognitive outcomes. Among them, there were some well-known types with beneficial effects. They include Dietary Approaches to Stop Hypertension (DASH), Mediterranean diet, Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) [5], Low carbohydrate diet (LCD) [6]. In the light of LCD, the authors and colleagues have reported clinical studies for LCD so far. We have developed three meal types of LCD, which are super-, standard- and petite-LCD [6]. These LCD have been widely prevalent through the activity of Japan LCD promotion association (JLCDPA) [6].

There have been several factors involving pathophysiological cause for Type 2 Diabetes Mellitus (T2DM) and Alzheimer’s Disease (AD). The presence of inflammation, defective insulin signaling, and mitochondrial dysfunction has been associated with obesity and the enhancement of stress signals [7]. Similarly, chronic inflammation in the brain has been supposed to contribute the development of the pathology of AD. Consequently, both of these could be suggested to be one of the risks of common molecular pathology [8].

Citation: BANDO H (2019) Close Relationship of Alzheimer’s Disease (AD) and Glucose Dysregulation. Int Arch Endocrinol Clin Res 5:016. doi.org/10.23937/2572-407X.1510016
Accepted: June 01, 2019; Published: June 03, 2019

Several evidence have been reported about dietary types on cognitive outcomes. Among them, there were some well-known types with beneficial effects. They include Dietary Approaches to Stop Hypertension (DASH), Mediterranean diet, Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) [5], Low carbohydrate diet (LCD) [6]. In the light of LCD, the authors and colleagues have reported clinical studies for LCD so far. We have developed three meal types of LCD, which are super-, standard- and petite-LCD [6]. These LCD have been widely prevalent through the activity of Japan LCD promotion association (JLCDPA) [6].

There have been several factors involving pathophysiological cause for Type 2 Diabetes Mellitus (T2DM) and Alzheimer’s Disease (AD). The presence of inflammation, defective insulin signaling, and mitochondrial dysfunction has been associated with obesity and the enhancement of stress signals [7]. Similarly, chronic inflammation in the brain has been supposed to contribute the development of the pathology of AD. Consequently, both of these could be suggested to be one of the risks of common molecular pathology [8].

Citation: BANDO H (2019) Close Relationship of Alzheimer’s Disease (AD) and Glucose Dysregulation. Int Arch Endocrinol Clin Res 5:016. doi.org/10.23937/2572-407X.1510016
Accepted: June 01, 2019; Published: June 03, 2019

Copyright: © 2019 BANDO H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dementia. There were studies concerning glycemic control and the onset of dementia. Among these, ACCORD-MIND (Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study) has been known. As a result, no significant difference was found in the effect on cognitive function in the intensive treatment group (goal with A1c < 6.0%) compared to the standard treatment group (goal with A1c 7.0-7.9%) [11]. Similar results were observed with other reports [12]. There are few large-scale Randomized Controlled Trials (RCTs) of diabetes management including cognitive function as an endpoint. Consequently, it has been not clear whether strict management is effective for preventing the onset of dementia [1].

As for the relationship between glycemic control and dementia, the risk for developing dementia has been higher in the cases with severe hypoglycemic seizures. Conversely, the risk of severe hypoglycemic seizures has been higher in the cases with dementia [13]. Thus, both factors may interact each other to cause a vicious cycle. Consequently, prevention of hypoglycemia and stable glucose variability have been important according to the guideline of diabetic management [14].

There was a study for the patients with MCI or dementia due to AD, in which anti-diabetic agent metformin was provided [15]. As a result, metformin seemed to show improved executive function, associated with probable improvement of function for learning, memory and attention.

A study of a systematic review and meta-analysis was reported for the relationship between obesity and dementia [16]. From 1612 abstracts and 21 completely met the criteria, the result was that obesity with < 65 years showed a positive association on dementia with Risk Ratio (RR) 1.41. In contrast, the opposite result was found in those aged 65 and over as RR 0.83 [16]. Thus, the relationship between obesity and dementia varies with age.

There are various controversies concerning the relationship between Total Cholesterol (TC) value and increased risk of AD. Meta-analyses were conducted including 17 studies, 23,338 participants for 20 years [17]. The evaluation would vary by each study. For middle-aged studies, the results showed significant correlations. In contrast, studies for older subjects tended to show less significant correlations. Consequently, it seemed to be depending on the age of the subjects [17]. In general, cases of high TC in middle age may increase the risk of AD in later life or may increase the onset of AD pathology. Furthermore, there are many reports that HDL-C and triglyceride levels in the elderly are not related to the elevated risk of dementia [17].

Can administration of statins for the patients with dyslipidemia suppress the onset of dementia? Cochrane review analyzed two large-scale RCTs in high-risk patients (n = 26,340) with vascular disease [18]. As a result, statin administration in the elderly could not prevent the onset of dementia and the decline in cognitive function.

With regard to the blood pressure, age-related hypertension is significantly associated with dementia and AD onset. In the patients with dementia and MCI on the Antihypertensive Drugs (AHDs), cognitive function declines when daytime blood pressure has been lower. Furthermore, the progress for decreased cognitive function has been reported to be significantly faster [19]. Thus, excessive depression may reduce cognitive function.

In previous studies such as traditional Systematic Review (SR) and Meta-Analysis (MA), high physical activity has been shown to reduce the risk of dementia and cognitive decline [20]. In contrast, there has been an opposite report. The Cochrane Review concludes that the analysis of MA does not clearly show the evidence for its effectiveness on cognitive function in the patients with dementia [21].

There is a large RCT for aged patients with dementia. It has been Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Among them, modifiable vascular and lifestyle-related risk factors have been analyzed [22]. As a result, it has supposed that multi-domain intervention would relieve or maintain the cognitive function in elderly people with risk for dementia.

In summary, various health and medical problems including diabetes, dementia and MCI have been discussed. There are not simple and effective way to solve these complex problems. With multi-factorial analyses and integrative approach, multi-domain interventions would become the recommended treatments for clinical practice and research in the future.

References
1. Cho NH, Shaw JE, Karuranga S, Huang Y, Da Rocha Fernandes JD, et al. (2018) IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138: 271-281.
2. Vlachos GS, Scarmeas N (2019) Dietary interventions in mild cognitive impairment and dementia. Dialogues Clin Neurosci 21: 69-82.
3. Scarmeas N, Anastasiou CA, Yannakoulia M (2018) Nutrition and prevention of cognitive impairment. Lancet Neurol 17: 1006-1015.
4. Bando M, Bando H (2019) The influence of unsaturated fatty acids for atherosclerosis in recent years. J Obesity and Diabetes 3: 9-11
5. Hosking DE, Eramudugolla R, Cherbuin N, Anstey KJ (2019) MIND not Mediterranean diet related to 12-year incidence of cognitive impairment in an Australian longitudinal cohort study. Alzheimer’s & Dementia 15: 581-589.
6. Ebe K, Bando H, Yamamoto K, Bando M, Yonei Y (2018) Daily carbohydrate intake correlates with HbA1c in low carbohydrate diet (LCD). J Diabetol 1: 4-9.
7. De Felice FG, Ferreira ST (2014) Inflammation, defective
insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63: 2262-2272.

8. Wakabayashi T, Yamaguchi K, Matsu K, Sano T, Kubota T, et al. (2019) Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease. Mol Neurodegener 14: 15.

9. Abolhassani N, Leon J, Sheng ZJ, Oka S, Hamasaki H, et al. (2017) Molecular pathophysiology of impaired glucose metabolism, mitochondrial dysfunction, and oxidative DNA damage in Alzheimer’s disease brain. Mech Ageing Dev 161: 95-104.

10. An Y, Varma VR, Varma S, Casanova R, Dammer E, et al. (2018) Evidence for brain glucose dysregulation in Alzheimer’s disease. Alzheimers Dement 14: 318-329.

11. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, et al. (2011) Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 10: 969-977.

12. Areosa Sastre A, Vernooij RW, González-Colaço Harmand M, Martínez G (2017) Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev 6: CD003804.

13. Mattishent K, Loke YK (2016) Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta-analysis. Diabetes, Obes Metab 18: 135-141.

14. American Diabetes Association (2018) Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care 41: 73-85.

15. Keenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, et al. (2017) Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study. Alzheimer Dis Assoc Disord 31: 107-113.

16. Pedditizi E, Peters R, Beckett N (2016) The risk of overweight/obesity in mid-life and late life for the development of dementia: a systematic review and meta-analysis of longitudinal studies. Age Ageing 45: 14-21.

17. Anstey KJ, Ashby-Mitchell K, Peters R (2017) Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis. J Alzheimers Dis 56: 215-228.

18. McGuinness B, Craig D, Bullock R, Passmore P (2016) Statins for the prevention of dementia. Cochrane Database Syst Rev 4: CD003160.

19. Mossello E, Pieraccioli M, Nesti N, Bulgaresi M, Lorenzi C, et al. (2015) Effects of Low Blood Pressure in Cognitively Impaired Elderly Patients Treated With Antihypertensive Drugs. JAMA Intern Med 175: 578-585.

20. Blondell SJ, Hammersley-Mather R, Veerman JL (2014) Does physical activity prevent cognitive decline and dementia?: A systematic review and meta-analysis of longitudinal studies. BMC Public Health 14: 510.

21. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, et al. (2015) Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement 11: 718-726.

22. Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, et al. (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385: 2255-2263.